类风湿关节炎试验与真实世界人群特征差异的系统评价
该系统评价通过系统文献检索比较了接受利妥昔单抗、托珠单抗或依那西普治疗的RA患者随机对照试验(RCT)与观察性研究的基线特征。结果显示观察性研究患者年龄大3.0岁、病程长3.1年、既往DMARD多1.6种、DAS-28低0.6,提示RCT疗效可能无法完全反映真实世界效果。
要点
- 观察性研究患者比RCT患者年龄大3.0岁、病程长3.1年、既往DMARD多1.6种。
- RCT患者DAS-28较观察性研究高0.6,但HAQ-DI略低,CRP和ESR略高。
- 女性比例和RF阳性率在RCT与观察性研究间无差异。
核心结论
- RCT与注册研究中的RA患者特征存在实质性系统差异,RCT疗效可能不能反映真实世界有效性。
研究设计与样本
- 系统文献评价,纳入接受利妥昔单抗、托珠单抗或依那西普治疗的RA随机对照试验和观察性研究。
- RCT数据采用固定效应荟萃分析,观察性研究数据采用随机效应荟萃分析,并评估基线特征随时间变化。
主要发现
- 与RCT患者相比,观察性研究患者平均年龄大3.0岁(P < 0.001)。
- 观察性研究患者RA病程长3.1年(P < 0.001),既往DMARD多1.6种(P = 0.001)。
- 观察性研究患者DAS-28较RCT患者低0.6(P < 0.001)。
- RCT患者CRP和ESR略高,HAQ-DI略低;女性比例和RF阳性率无差异。
- 随时间推移,RCT和注册研究患者DAS-28均下降0.08,HAQ-DI均下降0.04;RCT患者ESR和CRP随时间下降,观察性研究患者无此变化。
临床怎么用
- 解读RCT疗效数据时需考虑其与真实世界患者特征的差异,警惕疗效-有效性差距。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether patients with RA enrolled in randomized controlled trials (RCTs) and observational studies may differ in terms of characteristics that could modify treatment effects, leading to an efficacy-effectiveness gap. METHODS: We conducted systematic literature reviews to identify RCTs and observational studies with RA, treated with rituximab, tocilizumab or etanercept. We extracted baseline characteristics and compared the data of RCTs and observational studies using fixed-effects meta-analyses for the RCTs and random-effects meta-analyses for the observational studies. We also assessed whether the baseline characteristics changed over time. RESULTS: Compared with patients enrolled in RCTs, those from observational studies were on average 3.0 years older (P < 0.001), suffered from RA for 3.1 years longer (P < 0.001), had 1.6 more prior disease modifying drugs (P = 0.001), and had a lower DAS-28 (difference -0.6, P < 0.001). CRP and ESR levels were slightly higher in RCTs. The HAQ-Disability Index (HAQ-DI) score was slightly lower in the RCT group. No differences were found in the percentages of included females or RF positivity. Over time, we found a significant decrease of - 0.08 in DAS-28 and a decrease of - 0.04 in HAQ-DI both in patients in RCTs and in patients from registries. Furthermore, ESR and CRP declined over time in RCT patients, but not in patients participating in observational studies. CONCLUSION: There are substantial systematic differences in patient characteristics between RCTs and registries in RA. The efficacy seen in RCTs may not reflect real-world effectiveness.
引用
- Kilcher G, Hummel N, Didden EM, et al. Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries. Rheumatology (Oxford). 2018. PMID: 29149289. doi:10.1093/rheumatology/kex394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。